Sequoia Financial Advisors LLC Acquires New Shares in Stereotaxis Inc. $STXS

Sequoia Financial Advisors LLC acquired a new position in shares of Stereotaxis Inc. (NYSEAMERICAN:STXS) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 380,652 shares of the company’s stock, valued at approximately $700,000. Sequoia Financial Advisors LLC owned 0.39% of Stereotaxis at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in STXS. Deutsche Bank AG increased its holdings in shares of Stereotaxis by 10.6% in the fourth quarter. Deutsche Bank AG now owns 51,584 shares of the company’s stock worth $119,000 after acquiring an additional 4,948 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its position in shares of Stereotaxis by 47.0% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 17,801 shares of the company’s stock worth $41,000 after purchasing an additional 5,692 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Stereotaxis by 106.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after purchasing an additional 5,910 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Stereotaxis by 12.0% during the 3rd quarter. Bank of America Corp DE now owns 63,114 shares of the company’s stock valued at $196,000 after purchasing an additional 6,742 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Stereotaxis by 4.9% during the 4th quarter. Barclays PLC now owns 150,246 shares of the company’s stock valued at $346,000 after purchasing an additional 7,062 shares in the last quarter. 45.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $3.50 target price (down from $4.00) on shares of Stereotaxis in a research note on Wednesday, May 13th. Citigroup reaffirmed a “market outperform” rating on shares of Stereotaxis in a research note on Wednesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Stereotaxis presently has an average rating of “Buy” and a consensus price target of $3.88.

Stereotaxis Stock Performance

STXS stock opened at $1.55 on Monday. The stock has a 50-day moving average price of $1.81 and a two-hundred day moving average price of $2.01. The stock has a market cap of $151.79 million, a PE ratio of -6.46 and a beta of 1.34. Stereotaxis Inc. has a 1 year low of $1.46 and a 1 year high of $3.59.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.